News / Taiwan / cnyes
Analysts Trim 2026 EPS Forecast for PharmaEssentia to NT$25.68, Target Price Set at NT$1,502.92
Health Technology · Biotechnology · cnyes · 2026-09-11
6446
A recent FactSet survey shows analysts have lowered their 2026 EPS forecast for PharmaEssentia (6446-TW) to NT$25.68, with a target price of NT$1,502.92.
What Happened
Earnings Forecast Revision: According to the latest FactSet survey of 10 analysts, the median 2026 EPS forecast for PharmaEssentia (6446-TW) has been revised downward from NT$26.29 to NT$25.68.
Valuation Range: The estimates provided by analysts show a wide range of expectations, with the highest valuation reaching NT$30.97 and the lowest at NT$13.75, indicating varying outlooks on future profitability.
Target Price: Based on the consensus of the surveyed analysts, the current target price for PharmaEssentia is set at NT$1,502.92, reflecting the market's assessment of its long-term growth potential.
Investment Disclaimer: These figures are derived from FactSet data and are intended for informational purposes only, and should not be construed as professional investment advice.